NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced that it will present significant interim findings from its randomized Phase 1b FURTHER study on firmonertinib monotherapy. This presentation will take place at the prestigious 2024 annual World Conference on Lung Cancer (WCLC), scheduled for September 7-10 in San Diego, California.
The data will be featured as an oral presentation in the conference’s Presidential Symposium. This marks a pivotal moment for ArriVent, as the FURTHER study represents the first prospectively designed randomized clinical trial data for a small-molecule EGFR tyrosine kinase inhibitor in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations. These mutations are known to be challenging to treat, and firmonertinib’s potential to be a first-line monotherapy offers hope for improved outcomes.
The abstract, titled “FURTHER: A Global, Randomized study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations,” will be presented on Monday, September 9, 2024, from 8:58 am to 9:05 am PT during the Presidential Symposium 2 session. This session will take place in San Diego, CA.
In conjunction with the WCLC, ArriVent will also host a virtual webinar on September 9, 2024, at 4:30 pm ET to discuss the firmonertinib program in detail. This webinar aims to provide further insights into the data presented and the implications for future treatment options for NSCLC patients.
This presentation and subsequent webinar are highly anticipated as they could mark a significant advancement in the treatment of NSCLC, a disease with limited options for patients with specific genetic mutations. ArriVent BioPharma continues to spearhead innovation in precision oncology, striving to bring effective therapies to patients with high unmet medical needs.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.